annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 39G BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab
(BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients
(pts) with advanced, previously untreated, squamous non-small cell lung
cancer (NSCLC). (Abstract #7583)
L. Faoro, J. D. Hainsworth, D. A. Karlin, J. E. Huang, L. Fang, F. A. Scappaticci
Brd. 39H A randomized phase III study of cisplatin and docetaxel with or without
irinotecan in pts with advanced non-small cell lung cancer: Okayama Lung
Cancer Study Group OLCSG 0403. (Abstract #7584)
K. Kiura, M. Tabata, N. Takigawa, S. Kuyama, Y. Segawa, H. Kamei,
T. Shibayama, K. Hotta, K. Matsuo, M. Tanimoto
Brd. 40A Phase I study of regorafenib (BAY 73–4506), an inhibitor of oncogenic and
angiogenic kinases, administered continuously in patients (pts) with
advanced refractory non-small cell lung cancer (NSCLC). (Abstract #7585)
M. S. Kies, G. R. Blumenschein Jr., O. Christensen, T. Lin, A. W. Tolcher
Brd. 40B Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin
(CDDP) as a first-line treatment in patients with advanced non-small cell lung
cancer (NSCLC). (Abstract #7586)
T. Seto, Y. Ichinose, N. Yamamoto, K. Kaira, S. Negoro, T. Hida, K. Takeda,
N. Masuda, S. Yokota, M. Fukuoka
Brd. 40F Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin
tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab
(B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The
FALCON trial. (Abstract #7587)
E. B. Garon, F. F. Kabbinavar, J. A. Neidhart, J. D. Neidhart, N. Y. Gabrail,
M. R. Oliveira, S. P. Lu, J. Balkissoon
Brd. 40G A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully
human monoclonal antibody (MAb) targeting VEGFR-2, in combination with
paclitaxel and carboplatin as first-line therapy in patients (pts) with stage
IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #7588)
D. R. Camidge, M. S. Ballas, S. Dubey, M. Haigentz, P. J. Rosen, J. F. Spicer,
H. J. West, G. D. Shah, H. Youssoufian, A. C. Mita
Brd. 40H Phase II study of bavituximab plus paclitaxel and carboplatin in untreated
locally advanced or metastatic non-small cell lung cancer: Interim results.
(Abstract #7589)
R. Digumarti, A. V. Suresh, G. S. Bhattacharyya, L. Dasappa, J. Shan
Brd. 41A Linifanib treatment in patients with non-small cell lung cancer (NSCLC):
Phase II results. (Abstract #7590)
R. A. Soo, G. D. Goss, R. Salgia, B. Besse, D. R. Gandara, N. H. Hanna,
J. L. Ricker, J. Qian, D. M. Carlson, E. Tan
Brd. 41B First-line treatment (txt) with pemetrexed-cisplatin (PC), followed
sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr)
patients (pts) with advanced NSCLC: An open-label, randomized phase II
trial. (Abstract #7591)
J. Liang, M. Ahn, J. Kang, Q. Xiu, Y. Chen, C. Yang, N. Scheuer, C. Linn,
M. Orlando
Brd. 41C Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients
with non-small cell lung cancer (NSCLC). (Abstract #7592)
A. C. Mita, R. S. Heist, O. Aren, P. N. Mainwaring, L. Bazhenova, S. M. Gadgeel,
R. H. Blum, J. Polikoff, J. Biswas, M. A. Spear
Brd. 41D A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or
pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly
patients with advanced non-small cell lung cancer. (Abstract #7593)
D. R. Spigel, F. A. Greco, D. Shipley, T. J. Ervin, E. T. Lubiner, J. D. Peyton,
E. K. Barnes, D. S. Thompson, H. A. Burris III, J. D. Hainsworth
218